Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NVAX | US
-1.07
-7.29%
Healthcare
Biotechnology
30/06/2024
04/10/2024
13.61
14.46
14.70
13.18
Novavax Inc. a biotechnology company that promotes improved health by discovering developing and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges which is evaluating vaccines for COVID-19 influenza and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine NVX-CoV2373 under the brand names of Nuvaxovid Covovax and Novavax COVID-19 Vaccine Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax Inc. was incorporated in 1987 and is headquartered in Gaithersburg Maryland.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Strong Operating Margin (> 25%)
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
134.2%1 month
111.6%3 months
109.6%6 months
183.5%-
1.78
49.52
-0.54
0.13
-0.53
2.34
-
-240.84M
2.18B
2.18B
-
39.01
70.90
-2.10
-898.20
6.29
26.13
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.51
Range1M
4.13
Range3M
8.94
Rel. volume
1.10
Price X volume
102.57M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
IBRX | IBRX | Biotechnology | 3.43 | 2.39B | -3.92% | n/a | -143.04% |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 40.84 | 2.35B | -2.18% | n/a | 16.11% |
Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 45.02 | 2.35B | 3.61% | n/a | 3.62% |
Arrowhead Pharmaceuticals Inc | ARWR | Biotechnology | 18.82 | 2.34B | -2.08% | n/a | 137.39% |
KEROS THERAPEUTICS INC. | KROS | Biotechnology | 60.9 | 2.30B | -0.67% | n/a | 3.32% |
Vericel Corporation | VCEL | Biotechnology | 43.36 | 2.17B | 6.54% | 4.32K | 39.42% |
Centessa Pharmaceuticals plc American Depositary Shares | CNTA | Biotechnology | 15.94 | 2.05B | -1.97% | n/a | 29.85% |
Akero Therapeutics Inc | AKRO | Biotechnology | 28.24 | 2.04B | -3.32% | n/a | 4.54% |
Celldex Therapeutics Inc | CLDX | Biotechnology | 30.65 | 2.03B | 1.46% | n/a | 0.29% |
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 34.6 | 2.00B | -2.73% | 20.07 | 40.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.53 | 0.76 | Cheaper |
Ent. to Revenue | 2.34 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 49.52 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 109.64 | 74.67 | Riskier |
Debt to Equity | -0.54 | -1.82 | Expensive |
Debt to Assets | 0.13 | 0.26 | Cheaper |
Market Cap | 2.18B | 3.73B | Emerging |